Diagnose VAP carefully, choose empirical therapy from the local ICU antibiogram, cover MRSA and resistant Gram-negatives when indicated, and stop at 7 days.
At the bedside
- 1
Confirm clinically and microbiologically
Chest imaging (CXR/lung ultrasound), endotracheal aspirate semi-quantitative culture (or BAL/mini-BAL), blood cultures. Exclude atelectasis, pulmonary oedema, ARDS, PE.
- 2
Assess resistance risk
Prior IV antibiotics within 90 days, septic shock, ARDS before VAP, ≥ 5 days hospital stay before onset, acute RRT, known colonisation, local MDR prevalence (in most Indian ICUs: high).
- 3
Empirical therapy
≤ 1 h if shockPer ICU antibiogram. Without recent BL-BLI/carbapenem exposure: piperacillin-tazobactam 4.5 g q6h (or cefoperazone-sulbactam 3 g q12h). Recent BL-BLI/carbapenem exposure: meropenem ± polymyxin B (or colistin). Add vancomycin/linezolid if MRSA risk or MRSA > 10-20% locally.
- 4
Optimise dosing
Loading doses, extended infusion of beta-lactams, TDM for vancomycin/aminoglycosides; consider CRRT/ARC effects.
- 5
De-escalate at 48-72 h
Narrow to culture results; stop MRSA cover if cultures/nasal PCR negative; stop if alternative diagnosis.
- 6
Duration 7 days
7 days for most HAP/VAP regardless of organism if clinically improving (ICMR CRO guidance 7-10 days).
Empirical VAP (no recent BL-BLI)
Piperacillin-tazobactam
- Dose
- 4.5 g q6h over 3-4 h (first dose over 30 min)
- Preparation
- 4.5 g in 100 mL NS
- Worked example
- 70 kg normal renal function: 4.5 g at 00, 06, 12, 18 h, each over 3 h (33 mL/h)
VAP after BL-BLI exposure / ESBL
Meropenem
- Dose
- 1 g q8h (2 g q8h over 3 h for high MIC)
MRSA cover
Vancomycin
- Dose
- Load 25 mg/kg, then 15 mg/kg q8-12h; AUC 400-600
- Worked example
- 70 kg: 1,750 mg load over ~2 h, then 1 g q12h; level before 4th dose
MRSA alternative
Linezolid
- Dose
- 600 mg q12h
Calculators for this topic
References
- 1
- 2
- 3
- 4
- 5
- 6
Suspected VAP
Step 1 of ~7
Tracheal aspirate/BAL + blood cultures
Based on National Centre for Disease Control (DGHS, MoHFW) and Indian Council of Medical Research; Kalil AC, Metersky ML, Klompas M, et al. Educational use; follow local protocol.
Pathophysiology
Micro-aspiration of colonised oropharyngeal and gastric secretions past the cuff, biofilm on the endotracheal tube, and impaired mucociliary clearance lead to VAP; pathogens are predominantly Gram-negative (Klebsiella, Acinetobacter, Pseudomonas) in Indian ICUs.
Evidence
- IDSA/ATS 2016: 7 days for HAP/VAP, antibiogram-based empirical therapy, de-escalation [Kalil 2016].
- ERS/ESICM 2017 international HAP/VAP guideline [Torres 2017].
- NCDC/ICMR 2025 and ICMR CRO guidance 2022 give Indian empirical and directed regimens [NCDC 2025; ICMR 2022].
Controversies
- Diagnosis by clinical vs quantitative cultures; ventilator-associated tracheobronchitis treatment; inhaled antibiotics.
🇮🇳 India notes
- ICMR AMRSN surveillance shows high carbapenem resistance in Klebsiella pneumoniae and very high resistance in Acinetobacter baumannii in Indian ICUs; generating a unit antibiogram is essential.
- Cefoperazone-sulbactam is commonly used in India and is listed as a first-line VAP option in national guidelines.
References
- 1
- 2
- 3
- 4
- 5
- 6
Test yourself
Module quiz · score 70% to complete the module
Previous
Severe community-acquired pneumonia
Next
Carbapenem-resistant and MDR Gram-negative infections
Educational reference for trained clinicians. Check doses against your hospital protocol and the patient in front of you.